Abstract 1958P
Background
ADT is an established treatment for PCa, influencing different aspects of tumor biology. The study aimed to assess expression of EMT (E- and N-cadherins (cad)) and CSC (CD44, CD133) markers as well as androgen (AR) and estrogen (ERα, ERβ) receptors and transforming growth factor beta type II receptor (TβRII) (an EMT regulator) in localized PCa samples after ADT.
Methods
56 radical prostatectomy cases were analyzed. 15 of them had 3-6 months of ADT before surgery. Double immunofluorescent staining was used. For E-cad and CD44 staining intensity was assessed, for CD133 – presence of staining, for N-cad– weighed staining index (WSI) and for AR, ERα, ERβ and TβRII – total staining scores (TSS) per case.
Results
In the studied cohort expression of EMT and CSC markers didn’t differ significantly in cases after ADT and without it (pχ2=0.71 for CD133, pMann-Whitney>0,05 for all other markers), that may assume that at least at the early stage of PCa development short-term ADT doesn’t influence these phenotypes. AR and ER expression both in stroma and epithelium didn’t differ significantly, except for ERβ in cancer cells nuclei, that appeared to be higher after ADT (TSS 6.00 vs. 3.25, pMann-Whitney=0.042). Expression of TβRII appeared to be significantly higher for nuclear and lower for membranous staining in ADT cases (Mann-Whitney test, TSS 2.33 vs. 1.20, p=0.002 and 0 vs. 0.58, p<0.001, respectively). Only in ADT cases CD44 was significantly higher in CD133+ tumors, and N-cad WSI correlated with CD44 expression, while ERα in both stroma and cancer cells correlated with epithelial AR (r=0.55 and r=0.54, pSpearman<0,05), though these associations were not seen in cases without ADT. Also moderate direct correlation was seen between nuclear TβRII and E-cad (r=0.52, pSpearman<0,05). Markers expression in pre-ADT biopsies and their dynamic changes on ADT could not be assessed.
Conclusions
ADT influences TβRII and ERβ expression in cancer cells and also modulates EMT and CSC markers and regulators correlations, that may assume that though ADT alone is not sufficient to induce EMT or CSC phenotypes, it may modulate intra-tissue interactions of signaling cascades and alter cell responses to regulating signals.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Puchinskaya.
Funding
Belarusian Republican Foundation for Fundamental Research, grants No. M14M-143, M19M-123.
Disclosure
M. Puchinskaya: Financial Interests, Personal, Invited Speaker: Roche.
Resources from the same session
54P - BL-B01D1, an EGFR x HER3 bispecific antibody-drug conjugate (ADC), in patients with locally advanced or metastatic biliary tract carcinoma (BTC)
Presenter: Zhihao Lu
Session: Poster session 13
55P - Subsequent anticancer therapy (SAT) analysis from 3-year follow-up of the phase III TOPAZ-1 study of durvalumab plus gemcitabine and cisplatin in biliary tract cancer (BTC)
Presenter: Arndt Vogel
Session: Poster session 13
56P - Multi-omic profiling in cholangiocarcinoma to enable scientific advancement within the DKFZ/NCT/DKTK MASTER study
Presenter: Federico Nichetti
Session: Poster session 13
57P - Integrative analysis of the genomic and transcriptomic landscape identifies ciliary genes as a therapeutic target in bile duct cancer
Presenter: Pietro Carotenuto
Session: Poster session 13
58P - Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials
Presenter: Changhoon Yoo
Session: Poster session 13
59P - Prognostic score to predict recurrence after pancreaticoduodenectomy for ampullary carcinoma: Results from the French prospective FFCD cohort
Presenter: Gael Roth
Session: Poster session 13
60P - Baseline characteristics and molecular testing of patients with IDH1-mutated cholangiocarcinoma: Initial results from the phase IIIb ProvIDHe study
Presenter: Lorenza Rimassa
Session: Poster session 13
61P - Addressing racial disparities in clinical trials in cholangiocarcinoma
Presenter: Abhinav Vyas
Session: Poster session 13
Resources:
Abstract
62TiP - HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC)
Presenter: Teresa Macarulla Mercade
Session: Poster session 13
240P - Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2− early breast cancer (EBC) in NATALEE
Presenter: Michael Untch
Session: Poster session 13